Jan G Dohlman1, C Stephen Foster2,3, Claes H Dohlman3,4. 1. East Boston Neighborhood Health Center, East Boston, Massachusetts. 2. Massachusetts Eye Research and Surgery Institute, Cambridge, Massachusetts. 3. Harvard Medical School, Boston, Massachusetts. 4. Massachusetts Eye and Ear Infirmary, Boston, Massachusetts.
Abstract
PURPOSE: To report the case of a patient with Stevens-Johnson Syndrome (SJS) with Boston Keratoprosthesis (KPro) who may have benefited from infliximab infusions. MATERIALS AND METHODS: Patient A 34-year-old woman with a history of acute SJS at age 12 had three Boston KPro Type II implanted since 2003 into her right eye. The first two were followed by tissue necrosis and aqueous leak, necessitating reoperation. After the third device was implanted, monthly infliximab infusions were started. METHODS: Infliximab 5 mg/kg infusions were started in January 2008, repeated after 2 weeks, and then given monthly for a year. The treatment is continuing combined with regular eye examinations. RESULTS: While receiving infliximab, the skin around the keratoprosthesis has not shown a trace of retraction or necrosis. This is in sharp contrast to events following the two previous attempts at visual rehabilitation. The patient's vision has been generally stable for a year and is currently 20/30. CONCLUSION: A KPro in a patient with SJS normally has a poor long-term prognosis. However, retention of the prosthesis and visual outcome may benefit from monthly infliximab infusions.
PURPOSE: To report the case of a patient with Stevens-Johnson Syndrome (SJS) with Boston Keratoprosthesis (KPro) who may have benefited from infliximab infusions. MATERIALS AND METHODS: Patient A 34-year-old woman with a history of acute SJS at age 12 had three Boston KPro Type II implanted since 2003 into her right eye. The first two were followed by tissue necrosis and aqueous leak, necessitating reoperation. After the third device was implanted, monthly infliximab infusions were started. METHODS: Infliximab 5 mg/kg infusions were started in January 2008, repeated after 2 weeks, and then given monthly for a year. The treatment is continuing combined with regular eye examinations. RESULTS: While receiving infliximab, the skin around the keratoprosthesis has not shown a trace of retraction or necrosis. This is in sharp contrast to events following the two previous attempts at visual rehabilitation. The patient's vision has been generally stable for a year and is currently 20/30. CONCLUSION: A KPro in a patient with SJS normally has a poor long-term prognosis. However, retention of the prosthesis and visual outcome may benefit from monthly infliximab infusions.
Authors: Eric B Suhler; Justine R Smith; Michael S Wertheim; Andreas K Lauer; Daryl E Kurz; Terri D Pickard; James T Rosenbaum Journal: Arch Ophthalmol Date: 2005-07
Authors: Annie Joseph; Dev Raj; Harminder S Dua; Pauline T Powell; Peter C Lanyon; Richard J Powell Journal: Ophthalmology Date: 2003-07 Impact factor: 12.079
Authors: Claes H Dohlman; Cynthia L Grosskreutz; Teresa C Chen; Louis R Pasquale; Peter A D Rubin; Eva C Kim; Marlene Durand Journal: J Glaucoma Date: 2010-02 Impact factor: 2.503
Authors: J D Ament; T P Stryjewski; S Pujari; S Siddique; G N Papaliodis; J Chodosh; C H Dohlman Journal: Eye (Lond) Date: 2010-12-24 Impact factor: 3.775
Authors: Claes H Dohlman; Fabiano Cade; Caio V Regatieri; Chengxin Zhou; Fengyang Lei; Alja Crnej; Mona Harissi-Dagher; Marie-Claude Robert; George N Papaliodis; Dongfeng Chen; James V Aquavella; Esen K Akpek; Anthony J Aldave; Kimberly C Sippel; Donald J DʼAmico; Jan G Dohlman; Per Fagerholm; Liqiang Wang; Lucy Q Shen; Miguel González-Andrades; James Chodosh; Kenneth R Kenyon; C Stephen Foster; Roberto Pineda; Samir Melki; Kathryn A Colby; Joseph B Ciolino; Demetrios G Vavvas; Shigeru Kinoshita; Reza Dana; Eleftherios I Paschalis Journal: Cornea Date: 2018-02 Impact factor: 3.152
Authors: Marie-Claude Robert; Mathieu Frenette; Chengxin Zhou; Yueran Yan; James Chodosh; Frederick A Jakobiec; Anna M Stagner; Demetrios Vavvas; Claes H Dohlman; Eleftherios I Paschalis Journal: Transl Vis Sci Technol Date: 2016-03-11 Impact factor: 3.283